Market Performance - The chemical pharmaceutical sector increased by 1.95% on December 19, with XinNuoWei leading the gains [1] - The Shanghai Composite Index closed at 3890.45, up 0.36%, while the Shenzhen Component Index closed at 13140.22, up 0.66% [1] Top Gainers in Chemical Pharmaceutical Sector - XinNuoWei (300765) closed at 34.69, up 11.44%, with a trading volume of 311,700 shares and a transaction value of 1.069 billion [1] - KangYi Pharmaceutical (300086) closed at 11.02, up 11.43%, with a trading volume of 965,500 shares and a transaction value of 1.018 billion [1] - MuNanHai Pharmaceutical (000566) closed at 7.24, up 10.03%, with a trading volume of 1,325,900 shares and a transaction value of 914 million [1] Market Capital Flow - The chemical pharmaceutical sector saw a net inflow of 68.1822 million from institutional investors, while retail investors contributed a net inflow of 31.3 million [2] - The sector experienced a net outflow of 381 million from speculative funds [2] Individual Stock Capital Flow - ST Renfu (600079) had a net inflow of 92.7508 million from institutional investors, while it faced a net outflow of 26.4283 million from speculative funds [3] - GuangShengTang (300436) recorded a net inflow of 49.2520 million from institutional investors, with a net outflow of 17.4322 million from speculative funds [3] - KangZhi Pharmaceutical (300086) had a net inflow of 28.1873 million from institutional investors, while it faced a net outflow of 3.1280 million from retail investors [3]

| | 份 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 002644 | 佛慈制 | 10.06 | 4.83 | 9.04 | 9.52 | 5.33 | | | 药 | | | | | | | 688626 | 翔宇医 | 5.72 | 2.70 | 51.28 | 54.01 | 5.32 | | | 疗 | | | | | | | 002666 | 德联集 | 10.04 | 2.60 | 5.22 | 5.48 | 5.04 | | | 团 | | | | | | | 688648 | 中邮科 | 10.94 | 11.95 | 55.72 | 58.49 | 4.97 | | | 技 | | | | | | | 300878 | 维康药 业 | 13.01 | 6.18 | 22.86 | 23.98 | 4.92 | | 001368 | 通达创 | 7.45 | 17.53 | 24.62 | 25.83 | 4.91 | | | 智 | | | | | | | 300632 | 光莆股 | 4.61 | 8.83 | 1 ...

| 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 半年线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 300076 | GQY视 | 13.08 | 10.52 | 6.56 | 7.35 | 12.05 | | | 讯 | | | | | | | 688711 | 宏微科 技 | 12.34 | 15.68 | 25.03 | 27.50 | 9.88 | | 605003 | 众望布 艺 | 9.98 | 1.76 | 23.70 | 25.78 | 8.75 | | 002766 | 索菱股 份 | 9.96 | 11.09 | 5.38 | 5.85 | 8.75 | | 920943 | 优机股 份 | 9.39 | 19.03 | 26.17 | 28.20 | 7.78 | | 688326 | 经纬恒 润 | 13.11 | 4.16 | 103.11 | 111.07 | 7.72 | | 000826 | 启迪环 境 | 9. ...

（文章来源：证券时报网） | 600367 | 红星发 | 10.02 | 7.95 | 16.41 | 17.13 | 4.41 | | --- | --- | --- | --- | --- | --- | --- | | | 展 | | | | | | | 002363 | 隆基机 | 5.65 | 3.37 | 8.25 | 8.60 | 4.28 | | | 械 | | | | | | | 603001 | 奥康国 | 7.61 | 1.49 | 8.68 | 9.05 | 4.25 | | | 际 | | | | | | | 000679 | 大连友 | 7.00 | 2.69 | 8.53 | 8.87 | 3.95 | | | 谊 | | | | | | | 601089 | 福元医 | 5.64 | 0.87 | 23.42 | 24.33 | 3.89 | | | 药 | | | | | | | 603596 | 伯特利 | 6.36 | 2.18 | 48.96 | 50.85 | 3.86 | | | 利源股 | | | | | | | 002501 | 份 | 10.14 | 4.6 ...

NO.1 献血年龄拟延长至65周岁献血法修订草案公开征求意见 12月17日，国家卫生健康委发布公告，就献血法（修订草案征求意见稿）面向社会公开征求意见。献血 者年龄从提倡18周岁至55周岁，修订为提倡18周岁至65周岁的公民在符合健康要求的情况下自愿献血。 血站对献血者每次采集全血不得超过400毫升，两次采集全血间隔期从不少于6个月修订为不少于90天。 点评：新的献血草案提高了献血年龄的上限，并且缩短了全血捐献的间隔，有助于改善我国血液供应的 稳定性。 NO.2 同仁堂：未直接或间接持有南极磷虾油相关报道中提及的四川健康药业任何股权及投资权益 NO.3 亚虹医药：APL-2401临床试验申请获得国家药品监督管理局批准 12月17日，亚虹医药公告称，公司近日收到国家药品监督管理局签发的《药物临床试验批准通知书》， 公司APL-2401在FGFR2/3驱动的晚期实体瘤患者中开展I期临床试验申请获得批准。该款药物为全球同 步研发的1类创新药，审评审批环节仅22个工作日就获得批准，成为全国首批获得此项新政审批通过的 项目之一。 点评：亚虹医药APL-2401的临床试验通过"30日通道"加速落地，体现出政策对创新药的支 ...

据悉，APL-2401为全球同步研发的1类创新药，其国际多中心临床试验设计及申报资料符合国际临床试 验技术标准体系要求，成功纳入国家药监局于9月12日发布的《关于优化创新药临床试验审评审批有关 事项的公告》规定的"30日通道"，并以仅22个工作日获得批准，成为全国首批获得此项新政审批通过的 项目之一。 北京商报讯（记者 丁宁）12月17日晚间，亚虹医药（688176）发布公告称，公司收到国家药品监督管 理局（NMPA）签发的《药物临床试验批准通知书》，公司APL-2401（药物名称为ASN-8639片）在 FGFR2/3驱动的晚期实体瘤患者中开展I期临床试验申请获得批准。 ...

Group 1 - CICC is planning to absorb and merge Dongxing Securities and Xinda Securities through a share swap, with trading resuming on December 18, 2025 [1] - Victory Energy's major shareholder plans to transfer 29.99% of its shares to Qiteng Robotics, with no plans for asset restructuring in the next 12 months [2] - China Metallurgical Group intends to repurchase A-shares worth 1 to 2 billion yuan at a price not exceeding 4.9 yuan per share [3] Group 2 - Boten Co. plans to acquire part of the Yifeng Yunding Fund for 1 yuan, with a commitment to fulfill a 20 million yuan capital contribution [4] - Tongyou Technology has initiated a 50 million yuan accounts receivable factoring business [5] - Gaode Infrared has received approval to issue debt financing tools totaling up to 3 billion yuan [6] Group 3 - Zhengyu Industrial's application for a private placement of A-shares has been approved by the Shanghai Stock Exchange [7] - China CRRC signed contracts totaling approximately 53.31 billion yuan, accounting for 21.6% of its projected 2024 revenue [9] - High Energy Environment's director increased his stake by purchasing 56,100 shares [10] Group 4 - Shantou Technology received approval from the CSRC for a convertible bond issuance [11] - Puyang Co. plans to use up to 900 million yuan of idle funds for entrusted wealth management [12] - Huibai New Materials has been awarded a government subsidy of 3.8 million yuan, with the first installment of 2.12 million yuan already received [13] Group 5 - Jiayuan Technology's shareholders plan to transfer 2.51% of the company's shares through a pricing inquiry [14] - Lingpai Technology's subsidiary terminated a 125 million yuan procurement contract due to market changes [15] - Juguang Technology intends to use up to 200 million yuan of idle funds for cash management [16] Group 6 - Zhongwen Media's subsidiary terminated a 200 million yuan private equity fund subscription due to market changes [17] - Zhifei Biological's modified vaccine for monkeypox has received clinical trial acceptance [19] - GeKowei's subsidiary received a government subsidy of 60 million yuan, accounting for 32.12% of the company's audited net profit [20] Group 7 - Wantai Biological's application for a clinical trial of a respiratory syncytial virus vaccine has been accepted [21] - Haitai Technology plans to increase capital in its Thai joint venture from 500,000 to 3 million Thai baht [22] - Shanghai Airport signed contracts for the transfer of duty-free store operating rights [23] Group 8 - Del Shares received approval to issue shares for the acquisition of 100% of Aizhuo Intelligent [24] - Novozymes' products have obtained EU CE IVDR certification [25] - Shibai Testing's chairman's assistant plans to increase shareholding by 8 to 12 million yuan [26] Group 9 - Huitian New Materials plans to invest approximately 97.68 million yuan in a lithium battery anode glue project [27] - Pudong Construction's subsidiaries won contracts totaling 1.649 billion yuan [29] - Acolyte's subsidiary has entered trial production for a special high-temperature resistant resin project [30] Group 10 - Pingzhi Information's subsidiary signed a 38.25 million yuan computing power service contract [31] - Tianma Technology is required to pay 5.3625 million yuan in taxes and penalties [32] - Yahon Pharmaceutical's clinical trial application for GLX002 has been approved [34]

（文章来源：证券日报） 证券日报网讯 12月17日晚间，亚虹医药发布公告称，公司收到国家药品监督管理局（NMPA）签发的 《药物临床试验批准通知书》，公司APL-2401（药物名称为ASN-8639片）在FGFR2/3驱动的晚期实体 瘤患者中开展I期临床试验申请获得批准。 ...

Core Insights - The chemical pharmaceutical sector experienced a rise of 1.22% on December 17, with Hai Chen Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3870.28, up 1.19%, while the Shenzhen Component Index closed at 13224.51, up 2.4% [1] Group 1: Stock Performance - Hai Chen Pharmaceutical (300584) closed at 50.55, with a gain of 6.04% and a trading volume of 68,600 shares, amounting to a transaction value of 342 million yuan [1] - Other notable performers included Yahui Pharmaceutical (688176) with a closing price of 10.35, up 5.50%, and ST Renfu (600079) at 18.10, up 4.99% [1] - The overall trading volume and transaction values for various stocks in the sector indicate strong market activity, with ST Renfu recording a trading volume of 1.25 million shares and a transaction value of 2.173 billion yuan [1] Group 2: Fund Flow Analysis - The chemical pharmaceutical sector saw a net outflow of 554 million yuan from institutional investors, while retail investors contributed a net inflow of 799 million yuan [2][3] - The main stocks experiencing significant fund flow included ST Renfu, which had a net inflow of 112 million yuan from institutional investors, while Hai Chen Pharmaceutical saw a net outflow of 18.84 million yuan from retail investors [3] - The overall fund flow dynamics suggest a divergence in investment behavior between institutional and retail investors within the sector [2][3]

格隆汇12月17日丨亚虹医药(688176.SH)在投资者互动平台表示，公司营业收入主要来自国内，暂未直 接开展出口海外的业务。 ...